Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Characterizing the molecular basis of Perrault Syndrome
EF 2024-25
Résumé
The mitochondria has always been known as the "powerhouse of the cell," providing energy requirements to meet metabolic demands. Proteins within the mitochondria that sustain these processes must fold properly into their three-dimensional structure to perform their function. Proteins that are unable to fold into their native state must be removed by so-called proteases which are enzymes that degrade damaged or misfolded proteins. Of notable importance is the caseinolytic protease P (ClpP) which is found in the mitochondria. Genetic mutations in ClpP has been implicated in a disease called Perrault syndrome, characterized by sensorineural hearing loss, epilepsy, intellectual disability, ataxia (uncoordinated movement), neuropathology, ovarian dysfunction in females and lack of sperm production in males.
The Houry Lab specializes in uncovering the mechanism by which ClpP functions and regulates mitochondrial health. For this proposal, we are investigating how mutations in ClpP can give rise to Perrault syndrome.
First, we will characterize the protein structural stability of these ClpP mutants and the rate at which they catalyze the degradation reactions to remove damaged or misfolded proteins. Secondly, we will employ stem cell lines and patient cells which we have access to courtesy of our collaborator Dr. William Newman, a clinician from the United Kingdom. Some examples of experiments that will be performed include observing the localization of these ClpP mutants in the mitochondria, identifying what protein targets are not being efficiently cleared by the ClpP mutants and how the mitochondrial energetics, metabolism and health are affected.
By understanding how mutations in ClpP from a mechanistic and functional point of view can contribute to Perrault syndrome, this will facilitate the discovery of novel therapeutics in the hope of ameliorating patient prognosis.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518351
Name
Aljghami Mazen E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterizing the molecular basis of Perrault Syndrome
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Enzymatic Degradation Assays (Michaelis-Menten Kinetics); Immunostaining And Immunoblotting; Mitochondrial Health; Perrault Syndrome; Primary Cell Lines And Induced Pluripotent Stem Cells; Protein Homeostasis (Proteostasis); Protein Misfolding; Protein Purification; Proteomics And Transcriptomics; X-Ray Crystallography
Abstract
The mitochondria has always been known as the "powerhouse of the cell," providing energy requirements to meet metabolic demands. Proteins within the mitochondria that sustain these processes must fold properly into their three-dimensional structure to perform their function. Proteins that are unable to fold into their native state must be removed by so-called proteases which are enzymes that degrade damaged or misfolded proteins. Of notable importance is the caseinolytic protease P (ClpP) which is found in the mitochondria. Genetic mutations in ClpP has been implicated in a disease called Perrault syndrome, characterized by sensorineural hearing loss, epilepsy, intellectual disability, ataxia (uncoordinated movement), neuropathology, ovarian dysfunction in females and lack of sperm production in males.
The Houry Lab specializes in uncovering the mechanism by which ClpP functions and regulates mitochondrial health. For this proposal, we are investigating how mutations in ClpP can give rise to Perrault syndrome.
First, we will characterize the protein structural stability of these ClpP mutants and the rate at which they catalyze the degradation reactions to remove damaged or misfolded proteins. Secondly, we will employ stem cell lines and patient cells which we have access to courtesy of our collaborator Dr. William Newman, a clinician from the United Kingdom. Some examples of experiments that will be performed include observing the localization of these ClpP mutants in the mitochondria, identifying what protein targets are not being efficiently cleared by the ClpP mutants and how the mitochondrial energetics, metabolism and health are affected.
By understanding how mutations in ClpP from a mechanistic and functional point of view can contribute to Perrault syndrome, this will facilitate the discovery of novel therapeutics in the hope of ameliorating patient prognosis.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Aljghami, Mazen E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~